替格瑞洛作为一种新型抗血小板药物，常与阿司匹林联用治疗急性冠脉综合征或有心肌梗死病史且伴有至少一种动脉粥样硬化血栓形成事件高危因素的患者，但对于亚洲人群可伴随更高的出血风险，为此越来越多的研究聚焦于低剂量替格瑞洛的疗效和安全性。系统检索了国内外有关低剂量替格瑞洛联合阿司匹林在冠心病患者中的临床应用，对文献进行整理，从对血小板功能的影响，治疗急性冠脉综合征、稳定型冠心病的效果以及药物安全性的角度，对不同治疗方案的临床效果进行评价，并对当前正在进行的研究以及未来的研究方向进行展望。

As a new type of antiplatelet drug, ticagrelor is often used in combination with aspirin to treat patients with acute coronary syndrome or a history of myocardial infarction accompanied by at least one high-risk factor for atherosclerotic thrombosis events. But for Asian populations, ticagrelor displayed a higher risk of bleeding. For this reason, more and more studies have focused on the efficacy and safety of low-dose ticagrelor. This review systematically searched the clinical studies of low-dose ticagrelor combined with aspirin in patients with coronary heart disease. We reviewed these literatures, and evaluated the clinical effects of different therapeutic regimens. From the aspects of the effect on platelet function, the effect of treating acute coronary syndrome and stable coronary heart disease, and drug safety, the current ongoing research and future research directions were looked forward.<

R972

天津市医院协会医院管理研究项目（20192203）